GEM231

04/01/2000 - "Preclinically, GEM231 inhibited human cancer xenografts either alone or synergistically with chemotherapeutic agents and has demonstrated an improved metabolic stability and safety profile compared to the first-generation compounds. "
04/01/2000 - "Objectives of this study were to define the safety profile and pharmacokinetics of GEM231 administered as 2-h IV infusions twice weekly in patients with refractory solid tumors. "
09/15/2003 - "Fourteen cancer patients received escalating doses of GEM231 as a 3-day (1 patient) or a 5-day continuous i.v. infusion (13 patients) at doses ranging from 80 to 180 mg/m(2)/day. "
09/01/2000 - "In addition to antitumor effects, when used as a single agent in animal tumor models, GEM-231 has also demonstrated potentiation of the effects of certain conventional cytotoxic chemotherapy drugs [230699]. "
06/01/2003 - "At this time, a phase I/II trial of GEM-231 in combination with irinotecan (CPT-11) was initiated in patients with solid tumors. "

03/01/2003 - "This study investigated the utility of a combinatorial therapy consisting of the RNA-DNA second-generation RIalpha antisense HYB0165 (Gem231) and the cytotoxic drug hydroxycamptothecin (HCPT), which inhibits topoisomerase I. LS-174T colon carcinoma and PC3M androgen-insensitive prostate cancer cells were used as experimental models. "

03/01/2003 - "This study investigated the utility of a combinatorial therapy consisting of the RNA-DNA second-generation RIalpha antisense HYB0165 (Gem231) and the cytotoxic drug hydroxycamptothecin (HCPT), which inhibits topoisomerase I. LS-174T colon carcinoma and PC3M androgen-insensitive prostate cancer cells were used as experimental models. "

09/15/2003 - "Low-grade fatigue was common (57%), cumulative by weeks 4-6, and reversible after GEM231 discontinuation. "